ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1867

Two-Year Diagnostic Consistency in Patients with Chronic Back Pain Suspected of Axial Spondyloarthritis in Protocolised Follow-up: Data from the Spondyloarthritis Caught Early Cohort

Anne Boel1, Miranda van Lunteren2, Karen Fagerli3, Ulf Lindström4, Roberta Ramonda5, Marleen van de Sande6, Désirée van der Heijde7 and Floris van Gaalen8, 1Leiden University Medical Centre, Hooge Zwaluwe, Netherlands, 2Leiden University Medical Centre, Weesp, Netherlands, 3Diakonhjemmet Hospital, Oslo, Norway, 4Department of Rheumatology and inflammation research, Institute of Medicine, Sahlgrenska University Hospital, University of Gothenburg, Gothenburg, Sweden., Gothenburg, Sweden, 5University of Padova, Padova, Italy, 6Amsterdam UMC, AMC/University of Amsterdam, Department of Rheumatology and Clinical Immunology, Amsterdam Infection & Immunity Institute and Amsterdam Rheumatology and Immunology Center (ARC), Amsterdam, Netherlands, 7Leiden University Medical Center, Leiden, Netherlands, 8Leiden University Medical Center (LUMC), Leiden, Netherlands

Meeting: ACR Convergence 2020

Keywords: Ankylosing spondylitis (AS), Back pain, spondyloarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2020

Title: Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster III: Axial SpA

Session Type: Poster Session D

Session Time: 9:00AM-11:00AM

Background/Purpose: A diagnosis of (early) axial spondyloarthritis (axSpA) is based on pattern recognition, which can be challenging and may change over time. The aim of this study was to investigate consistency of diagnosis over two years in patients with chronic back pain (less than two years symptoms) suspected of axSpA.

Methods: In the SPACE cohort, patients over 16 years of age referred to the rheumatology outpatient clinic with chronic back pain (≥3 months and < 2 years) starting before the age of 45, suspected of axSpA were included. Follow-up was performed only in patients with at least two SpA features or one SpA feature with a positive likelihood ratio ≥6.4 (Rudwaleit, van der Heijde, Khan, Braun, & Sieper, 2004). 

According to protocol, all SpA features as well as MRI and radiographs of the sacroiliac joints were performed at baseline and two years. Physicians were asked to report whether the diagnosis was axSpA or no axSpA at both timepoints, for which they had information available on all SpA features and locally read imaging.

Only patients with complete data on diagnosis and imaging at baseline and 2 years were included.

Patients were labelled with a consistent axSpA diagnosis if they had a diagnosis of axSpA at baseline and at two-year follow-up. Those patients whose diagnosis switched from axSpA to no axSpA; or from no axSpA to axSpA were labelled inconsistent axSpA diagnosis.

Results: Over two years the diagnostic consistency rate was 84%. The rate of change from axSpA to no axSpA was 9% and from no axSpA to axSpA 7% (table 1).

The patients who only had an axSpA diagnosis at baseline were more often female and less often HLA-B27 positive compared to the other two groups (table 2).

Furthermore, both groups with an inconsistent diagnosis had fewer SpA features and a lower level of confidence of the diagnosis (LoC) compared to the group with a consistent diagnosis of axSpA, especially at baseline.

At two-year follow-up the LoC in the group with an axSpA diagnosis at 2 years only was much lower than in the other two groups. In the group that only had an axSpA diagnosis at baseline, the LoC regarding the diagnosis increased most compared to baseline: physicians were more certain of the diagnosis no axSpA at two-year follow-up than they were of the diagnosis axSpA at baseline.  

The number of patients with sacroiliitis on radiographs and MRI was much higher in the group with a consistent diagnosis of axSpA. Although the percentage of patients with sacroiliitis on MRI increased in the group with a diagnosis of axSpA at two-year follow-up only, this was still much lower (21%) as compared to the patients with a consistent diagnosis (81%). This was in line with a low LoC in this group.

Conclusion: In a cohort of patients with chronic back pain suspected of axSpA the diagnostic consistency rate was high. Interestingly, in the group that only had a diagnosis axSpA at baseline, rheumatologists were more certain about the absence of axSpA at two years than the presence of axSpA at baseline.

Table 1 Consistency of diagnosis over 2 years

Table 2 Characteristics at baseline and 2-year follow up of the group with a consistent diagnosis over 2 years and the groups whose diagnosis changed between baseline and 2-year follow up


Disclosure: A. Boel, None; M. van Lunteren, None; K. Fagerli, None; U. Lindström, None; R. Ramonda, None; M. van de Sande, Boehringer Ingelheim, 2, AbbVie, 5, Eli Lilly, 2, 5, MSD, 5, 8, Janssen, 2, Novartis, 2, 5, 8; D. van der Heijde, AbbVie, 5, Bristol-Myers Squibb, 5, Cyxone, 5, Galapagos NV, 5, Gilead Sciences, Inc., 5, GlaxoSmithKline, 5, Eli Lilly, 5, Novartis, 5, Pfizer, 5, UCB Pharma, 5, Amgen Inc., 5, Astellas, 5, AstraZeneca, 5, Boehringer Ingelheim, 5, Celgene, 5, Daiichi-Sankyo, 5, Janssen, 5, Merck, 5, Regeneron, 5, Roche, 5, Sanofi, 5, Takeda, 5, Imaging Rheumatology bv, 3, Eisai, 5; F. van Gaalen, Reuma Nederland, 1, Stichting vrienden van Sole Mio, 1, MSD, 1, Abbvie, 1, Novartis, 1.

To cite this abstract in AMA style:

Boel A, van Lunteren M, Fagerli K, Lindström U, Ramonda R, van de Sande M, van der Heijde D, van Gaalen F. Two-Year Diagnostic Consistency in Patients with Chronic Back Pain Suspected of Axial Spondyloarthritis in Protocolised Follow-up: Data from the Spondyloarthritis Caught Early Cohort [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/two-year-diagnostic-consistency-in-patients-with-chronic-back-pain-suspected-of-axial-spondyloarthritis-in-protocolised-follow-up-data-from-the-spondyloarthritis-caught-early-cohort/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/two-year-diagnostic-consistency-in-patients-with-chronic-back-pain-suspected-of-axial-spondyloarthritis-in-protocolised-follow-up-data-from-the-spondyloarthritis-caught-early-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology